Find information on thousands of medical conditions and prescription drugs.

Varicella Zoster

The varicella-zoster virus (VZV), also known as human herpesvirus 3 (HHV-3), is one of the eight herpesviruses known to affect humans (and other vertebrates). Primary VZV infection results in chickenpox (varicella), which may rarely result in complications including VZV encephalitis. Even when clinical symptoms of varicella have resolved, VZV remains dormant in the nervous system of the host in the trigeminal and dorsal root ganglia. more...

VACTERL association
Van der Woude syndrome
Van Goethem syndrome
Varicella Zoster
Variegate porphyria
Vasovagal syncope
VATER association
Velocardiofacial syndrome
Ventricular septal defect
Viral hemorrhagic fever
Vitamin B12 Deficiency
VLCAD deficiency
Von Gierke disease
Von Hippel-Lindau disease
Von Recklinghausen disease
Von Willebrand disease

In about 10-20% of cases, VZV reactivates later in life to produce herpes zoster (shingles) and its associated sequelae including: post-herpetic neuralgia, zoster multiplex, myelitis, herpes ophthalmicus, or zoster sine herpete.

VZV is closely related to the herpes simplex viruses (HSV), sharing much genome homology. The known envelope glycoproteins (gB, gC, gE, gH, gI, gK, gL) correspond with those in HSV, however there is not equivalent of HSV gD. VZV virons are spherical and 150-200 nm in diameter. Its lipid envelope encloses the nucleocapsid of 162 capsomeres arranged in a hexagonal form. Its DNA is a single linear, double strand molecule, 125,000 nt long.

The virus is very susceptible to disinfectants, notably sodium hypochlorite. Within the body it can be treated by a number of drugs and therapeutic agents including aciclovir, zoster immunoglobulin (ZIG), and vidarabine.

A live attenuated VZV Oka/Merck strain vaccine is available and is marketed under the trade name Varivax. It was developed by Merck, Sharp & Dohme in the 1980s from the Oka strain virus isolated and attenuated by Michiaki Takahashi and colleagues in the 1970s. It was submitted to the U.S. Food and Drugs Administration for approval in 1990 and was approved in 1995. Since then, it has been added to the recommended vaccination schedules for children in Australia, the United States, and many other countries, causing controversy because it is only expected to be effective for about twenty years, leaving adults vulnerable to the most dangerous forms of infection by this virus, whereas getting normal chickenpox as a child typically leaves them immune for life.


[List your site here Free!]

From Revista do Instituto de Medicina Tropical de Sao Paulo, 5/1/05 by Lafer, Manuel Mindlin


The purpose of the study was to estimate the prevalence of IgG antibodies against varicella zoster virus (VZV) in the two most populated indigenous ethnic groups from Xingu Indigenous National Park, in Brazil, prior to the introduction of vaccination against the disease, and to determine the positive and the negative predictive values of a history of varicella infection. In 2001, 589 inhabitants of two Kuikuro villages and three Kaiabi villages were evaluated and provided information concerning previous varicella infection. An indirect immunosorbent assay (ELISA) to detect IgG anti-VZV antibodies was performed in 224 blood samples - volunteer selection had no interference of anamnesis. IgG prevalence was 80.8% (95% Confidence Interval: 76% - 86%). The seroepidemiology of varicella in Xingu National Park prior to varicella vaccine introduction was comparable to the Brazilian national seroprevalence described in the literature, and so were the positive (98%) and the negative predictive value (41%) of the referred history.

KEYWORDS: Varicella Zoster; Antibodies; Brazilian native Indians.


Varicella is a very contagious and vaccine preventable disease, occurring mostly during childhood, as a consequence of primary infection of varicella zoster virus (VZV)2,8,13. Although it usually presents a benign course, it may cause complications, especially in high risk individuals2-3,8,13. Morbidity and mortality due to varicella are significantly higher in adults13.

Studies on seroprevalence in tropical countries demonstrate a greater proportion of adolescents and adults susceptible to varicella, and with higher risk of complications, when compared with those of temperate countries2,13. In these countries, indirect immunosorbent assay (ELISA) used to detect IgG VZV antibodies have demonstrated prevalence equal to or higher than 90%1,9,16,21,27,30-31. In Brazil, general surveys have shown a seroprevalence of 85.4%10 and 94.2%26, closer to the pattern observed in temperate countries.

Nowadays, the Brazilian Indigenous population is 350,000 inhabitants from 218 different ethnic groups distributed in 554 discontiguous territories, occupying 12% of the National territory6,18,20. In 2000, an outbreak of varicella occurred in 94.6% of 278 Araweté Indians, in the state of Para, with 3% death (personnal communication). At Xingu National Park, a neighboring area, there was a varicella outbreak in 1999, reaching 5.8% of the inhabitants, 20% of whom were over 15 years of age. Seven patients (3.2%) presented severe forms of the disease (personal communication).

In view of that, Brazilian Ministry of Health decided to vaccinate the Native Indian population. The present study was undertaken to estimate the seroepidemiology of varicella at Xingu National Park immediately before the vaccine was introduced. That allowed us to compare the results in the Indian population with national ones. We have also calculated the positive predictive value of the previous history of varicella infection in order to assess whether that information would identify potential candidates for vaccination in Brazilian Indian population.


The study was performed between June and September 2001 at Xingu National Park, located North of the State of Mato Grosso, Brazil, encompassing an area of 2,642,003 hectares, where 14 ethnic groups live. The most populated of the indigenous ethnic groups are the Kuikuro, living in the Upper Xingu region, south of the Park, and the Kaiabi, living in the Lower Xingu region, north of the Park12,19. Kuikuro Indians are autochthonous, their settling records going back to a period between 200 B.C.and 800 A.D.15. On the other hand, the Kaiabi population of the Park migrated after 1949, most of them after 196114.

Selection of visited communities was done together with the Council of Indigenous Leaders, acknowledged by the Health Ministry12. Written consent was obtained by the Park leaders, the community chiefs and the indigenous health agents.

The population of Xingu National Park at the time was 3919 inhabitants (personal communication). Three Kaiabi communities were visited ("Capivara", "Guarujâ" and "Tuiararé") in Lower Xingu, and two Kuikuro communities ("Afukuri" and "Kuikuro") in Upper Xingu, amounting to 589 individuals (94.5% of the population of these communities).

All subjects were questioned regarding previous history of varicella infection; the answers were preferably given by individuals, but they were also given by relatives or indigenous health agents. Of note, this survey was carried out prior to the introduction of varicella vaccine.

Two hundred and twenty four blood samples were collected (38% of the individuals of the survey) through recruitment method, at each home, without interference of the answer given to anamnesis, and following the same age distribution of the population of the Park. We restrained our selection to one in two individuals under 20 years of age and one in four individuals over 20 years of age, as determined by the aforementioned Council.

After blood sample collection, serum was obtained, kept at 2 °C to 8 °C and sent to the Research Laboratory of the Division Pediatric Infectious Diseases of the Federal University of São Paulo. There it was kept at -20 "C until analysis. An in house indirect immunosorbent assay was performed to detect IgG VZV antibodies2428. Because an internationally accepted antibody level that predicts previous contact with wild varicella zoster virus or vaccine is not available, we have established a cutoff based on antibody values assessed on sera from 12 month-old infants without evidence of previous VZV infection. Twentytwo children who had been regularly followed up from birth and did not have evidence of previous varicella infection assessed both by clinical examination and repeated sérologie testing during the first year of life were tested for varicella antibodies at 12 months of age. Cutoff value of 0.2 lU/mL was calculated by adding mean antibody levels (0.04 lU/mL) to three standard deviations (3 χ 0.04 IU/mL)24.

Statistical analysis was performed using Microsoft Excel(®) 2000, EPI INFO release 6, and SPSS release 10.0. Probabilities were assessed for 95% significance. Chi-square test and Fisher's exact test were used; Dunnett's test was used for non-comparable variance analysis, and Fleiss' test11 was used to obtain confidence interval of near 100% seroprevalences.


The prevalence of VZV antibodies in the whole sample was 80.8% [95% Confidence Interval (CI): 76% - 86%]. The prevalence in the different age groups is summarized in Table 1. We observe a continuous increment in seropositivity up to the 11 to 15 year age group. From that age on, only one 20-year-old woman presented a negative VZV serology.

Table 2 shows sample distribution and the percentage of seropositive individuals in each village. As confidence intervals suggest, seropositivity in Afukuri (Upper Xingu), Kuikuro (Upper Xingu) and Guaruja (Lower Xingu) communities were comparable (Chi-square test, p = 0.1595). Scropositivities in Capivara and Tuiararé communities (both in Lower Xingu) were also comparable (Fisher's exact test, p = 0.5915). Comparison between the first group of three communities and the second one with two communities demonstrated a different seropositivity (Chi-square test, p

Previous history of varicella infection had a 98% positive predictive value (lower 95% CI: 95%), and a 41% negative predictive value (as derived from Table 3). No differences were noticed between males and females (Chi-square test, ρ = 0.94). Positive predictive value of the previous varicella history was 100% in subjects at the age of one to five years old, 94% in subjects at the age of six and 10 years old, and 100% in the group with subjects at the age of 11 or over.


In Brazil, varicella is popularly known as catapora, rather than varicella (or chickenpox), which means irrupted fire in Tupi language17, the "general language" in which indigenous people from different tribes used to communicate in Brazil. This is an evidence of the knowledge Brazilian indigenous groups have of the disease.

Prevalence of varicella was statistically comparable to that observed in a national study on seroprevalence, where a 85.5% prevalence was calculated in 3653 individuals between one and 40 years of age10. Varicella scropositivily in the Xingu population (57.1%), and Brazilian population (57.6%) between one and five years of age was comparable (Chi-square test, p = 0.9685). They were also comparable among six and 10 years old (78.9% in Xingu and 85.5% in Brazil; Chi-squarc lest, p = 0.179) and among 16 and 20 years old (97.1% in Xingu, and 95.5% in Brazil; Fisher's exact test, p = 0.53). In the population among 11 and 15 years old, two-tailed Fisher's exact test did not show any difference (p = 0.06): thus, the prevalence is also high in this age group in Xingu National Park, 100% (CI 95% 91% - 100%), as in the country, 91% (Cl 95% 88.7% - 93.2%).

Before this study, prevalence of varicella among indigenous people was evaluated in only one epidemiological study with the Tiriyo, who live in the north of Para State, in the border with Suriname. That was in the second half of the sixties, and the study demonstrated 80.4% of immunity in a sample of 51 individuals4-5.

We could not explain the difference in prevalence found in the two groups of villages, Upper (Afukuri and Kuikuro) and Lower (Capivara, Guarujá and Tuiararc) Xingu (Table 2). However, the differences in prevalence found in the study should not be attributed to internal migration, the habit of establishing new communities, the marriages among families of different communities or the changes in leaderships.

Negative predictive value of the history was 41% (Table 3), low and unreliable, as reported in the literature30. By contrast, positive predictive value of previous history of varicella in Xingu National Park was high, 98%, and it could be an efficient and economic measure to avoid vaccination, excluding from the "susceptible" category the individuals who referred previous varicella.

Other studies in Brazil have demonstrated different positive predictive values, ranging from 83.1 % in an age group from five months to 12 years29 'to 90.9% in medical students and nurses7, 95.1% in patients from one to 40 years'" and 100% in neonatal staff28. In view of that, CLEMENS et al. suggested that report of previous disease should be considered as a criterion to discard vaccination10.

The positive predictive value of a previous history of varicella is higher on temperate clime countries, where seroprevalence tends to be higher22. Previous studies, as this one, have shown that, for unknown reasons, Brazil has a higher varicella seroprevalence than would be expected for a tropical country22-23,25, and also a high positive predictive value of previous history of varicella.

In sum, we have shown that the seroprevalence of VZV is high in Brazilian Indigenous people, and comparable to the general prevalence found in Brazil. Despite the cultural differences and the difficulties in communication, the positive predictive value of a previous history of varicella proved to be high, suggesting it is a reliable method to discard vaccination.


Prevalência de anticorpos IgG contra ? virus varicela zoster nas aldcias indigcnas Kuikuro c Kaiabi do Parque Nacional do Xingu, Brasil, antes da vacinaçâo contra varicela

O objetivo do estudo foi aferir a prevalência de anticorpos IgG contra o Virus Varicela-Zoster (VVZ) nos dois grupos étnicos indfgenas mais povoados do Parque Nacional Indigena do Xingu, Brasil, antes da introduçâo da vacinaçâo contra a doença, e determinar os valores prcditivos positivo e negativo da historia de infecçâo de varicela. Em 2001, 589 habitantes de duas aldeias Kuikuro e très aldeias Kaiabi foram avaliados e forneceram dados referentes à infecçâo prévia por varicela. Um ensaio imunoenzimâtico indireto (ELISA) foi realizado em 224 amostras de sangue para detectar anticorpos IgG anti-VVZ - a selcçâo de voluntaries nâo teve interferência da anamnese. A prevalência de IgG foi de 80,8% (Intervalo de Confïança de 95%: 76% - 86%). A soroepidemiologia de varicela no Parque Nacional do Xingu antes da introduçâo da vacina foi comparâvel à soroprevalência nacional descrita na literatura, assim como os valores preditivos positivo (98%) e negativo (41%) da historia referida.


We thank Dr Douglas Rodrigues and Marilene Costa, from Indigenous Sanitarious Special Districts of Xingu and Altamira, respectively, for the data quoted under personal communication, which consisted in electronic mailing communication and written reports submitted to the Ministry of Health - whom we also acknowledge for providing data concerning the 2001 varicella epidemics among the Araweté Indians, provided by Marilia Rocha. We also thank Erika Ono for technical help with the anti-VZV in-house ELISA method and Dr Patricio Herrera, for the suggestions concerning statiscal analysis.


1. AEBI, C.; FISCHER, K.: GORGIEVSKI, M.; MATTER, L. & MÜHLEMANN, K. Age-specific seroprevaJence to varicella-zo.sier virus: study in Swiss children and analysis of European data. Vaccine, 19: 3097-3103, 2001.

2. AMERICAN ACADEMY OF PEDIATRICS - Varicella-zoster infections. In: PICKERING, L.K., ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26. ed. Illinois, Elk Grove Village, American Academy of Pediatrics, 2003. p. 672-686.

3. ARVIN, A.M. - Varicella-zoster virus. Clin. Microbiol. Rev., 9: 361-381, 1996.

4. BLACK, F.L.; HIERHOLZER, W.J.; PINHEIRO, EP. el al. - Evidence for persistence of infectious agents in isolated human populations. Amer. J. Epidcm., 100: 230-250, 1974.

5. BLACK, F.L.; WOODALL, J.P.; EVANS, A.S.; LIEBHABER, H. & HENLE, G. Prevalence of antibody against viruses in the Tiriyo, an isolated Amazon tribe. Amer. J. Epidcm., 91: 430-438. 1970.

6. BRAZILIAN MINISTRY OF HEALTH (Ministério da Saúde) [online] - FUNASA (Fundflção Nacional da Saúde). DSEI (Distrito Sanitário Especial Indígena); Map. Available at URL:

7. CARVALHO. E.R.M. - Estudo da soroprevalência de anticorpos anli-varicela zoster em estudantes de niedicina e enfermagem da Universidade do Brasil. Rio de Janeiro, 2002. (Disserlação de Mestrado - Faculdade da Medicina da Universidade do Brasil).

8. CENTERS FOR DISEASE CONTROL - Varicella. In: Epidemiology and prevention of vaccine-preventable diseases. 3. ed. Atlanta, CDC, 1996. p. 185-201.

9. CIOFFI DEGLI ATTI, M.L.; ROTA, M.C.; MANDOLINI, D. el al. - Assessment of varicella underreporting in Italy, Epidem. Infect., 128: 479-484, 2002.

10. CLEMENS, S.A.C.; AZEVEDO, T.; FONSECA, J.C. et al. - Seroepidemiology of varicella in Brazil : results of a prospective cross-sectional study. J. Pediat. (Rio de J.), 75: 433-441, 1999.

11. FLEISS, J.L. - Statistical methods for rates and proportions. 2. ed. New York, J. Wiley & Sons, 1981.

12. FUNASA (Fundação Nacional da Saúde) [online] - Distrito Sanitária Especial Indígena do Parque Indígena do Xingu. São Paulo, 2003. Available at URL: http://

13. GERSHON, A.A.; TAKAHASHI, M. & SEWARD, J. - Varicella vaccine. In: PLOTKIN, S.A. & ORENSTEIN. W.A., ed. Vaccine. 4. ed. Philadelphia. Saunders, 2004. p. 783-823.

14. GRÜNBERG G. - Contribuição para a etnografia dos Kayabí do Brasil central. Viena, 1970. (Dissertação de Mestrado - Universidade de Viena).

15. HECKENBERGER, M.J.; KUIKURO, A.; KUIKURO, U.T. el al. - Amazonia 1492: pristine forest or cultural parkland? Science, 301: 1710-1714, 2003.

16. HEININGER, U.; BRAUN-FAHRLÄNDER, C.; DESGRANDCHAMPS, D. et al. Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for scronegntivity. Pediat. infect. Dis. J., 20: 775-778, 2001.

17. HOUAISS. A.H. & VILLAR, M.S. - Dicionário Houaiss da lingua portuguesa. Rio de Janeiro, Objetiva, 2001.

18. IBGE (Instituto Brasileiro de Geografia e Estatística) [online] - Available at: URL: http:/ / .

19. ISA (Instituto Socioambiental) - Parque Indígena do Xingu. In: RICARDO, C.A., ed. Povos indigenas no Iirasil 1996/2000. São Paulo. Instituto Socioambiental, 2000. p. 628-660.

20. ISA (Instituto Socioambiental) [online] - Available at: URL: http://

21. KANRA, G.; TEZCAN, S.; BADUR, S. & TURKISH NATIONAL STUDY TEAM Varicella seroprevalence in a random sample of the Turkish population. Vaccine, 20: 1425-1428, 2002.

22. MacMAHON, E.; BROWN, L.J.; BEXLEY, S.; SNASHALL, D.C. & PATEL, D. Identification of potential candidates for varicella vaccination by history: questionnaire and seroprevalence study. Brit. med. J., 329: 551-552, 2004.

23. MUSHARRAFIEH, U.M.; NUWAYHID, I.A.; HAMADEH, G.N.; STEITIEH, S.W. & BIZRI, A.R.N. - Immunity to chickenpox among school adolescents in Lebanon and options for vaccination. Epidem. Infect., 129: 607-615, 2002.

24. ONO, E.; LAFER, M.M., WECKX, L.Y.; GRANATO, C. & DE MORAES-PINTO, M.I. - A simple and cheaper in house varicella zoster virus antibody indirect ELISA. Rev. Inst. Med. trop. S. Paulo, 46: 165-168, 2004.

25. OOI, P.L.; GOH, K.T.; DORAISINGHAM, S. & LINGA, A.E. - Prevalence of varicellazoster virus infection in Singapore. Southeast Asian J. trop. Med. publ. Hlth., 23: 22-25, 1992.

26. REIS. A.D.; PANNUTTI, C.S. & DE SOUZA, V.A.U.F. - Prevalence of varicella-zoster virus antibodies in young adults from different Brazilian climatic regions. Rev. Soc. bras. Med. trop., 36: 317-320, 2003.

27. SALLERAS, L.; DOMÍNGUEZ, A.; VIDAL, J. et al. - Seroepidemiology of varicellazoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine, 19: 183-188, 2000.

28. SANTOS, A.M.N.; ONO, E.; WECKX, L.Y.; COUTINHO, A.P. & DE MORAES-PINTO, M.I. - Varicella zoster antibodies in healthcare workers from two neonatal units in São Paulo, Brazil: assessment of a staff varicella policy. J. Hosp. Infect., 56: 228-231, 2004.

29. SEMENOVITCH, I. & LUPI, O. - A seroepidemiologic survey of the prevalence of varicella-zoster virus in the pediatric population in two university hospitals in Brazil. Int. J. Derm., 42: 193-196, 2003.

30. THIRY, N.; BEUTELS, P.; SHKEDY, Z. el al. - The Seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Europ. J. Pediat., 161: 588593, 2002.

31. WUTZLER, P.; FÄRBER, I.; WAGENPFEIL, S.; BISANZ, H. & TISCHER, A. Seroprevalence of varicella-zoster virus in German population. Vaccine, 20: 121-134, 2001.

Received: 17 December 2004

Accepted: 30 March 2005

Division of Pediatric Infectious Diseases, Federal University of São Paulo, Sao Paulo, SP, Brazil.

Correspondence to: Manuel Mindlin Lafer, Division of Pediatric Infectious Diseases, Federal University of São Paulo (UNIFESP-EPM), R. Pedro de Toledo 781, 9th floor, 04039-032 São Paulo, SP, Brazil. Tel/Fax: +55 11 55746471. E-mail:

Copyright Instituto de Medicina Tropical de Sao Paulo May/Jun 2005
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Varicella Zoster
Home Contact Resources Exchange Links ebay